Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer

Cancer Science

Volumn 104, Issue 3, 2013, Pages 337-344

  Takahashi, Ryota ^a   Hirata, Yoshihiro ^a   Sakitani, Kosuke ^a   Nakata, Wachiko ^a   Kinoshita, Hiroto ^a   Hayakawa, Yoku ^a   Nakagawa, Hayato ^a   Sakamoto, Kei ^b   Hikiba, Yohko ^b   Ijichi, Hideaki ^a   Moses, Harold L ^c,d   Maeda, Shin ^e   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE FOR ADULT DISEASES   (Japan)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CRE RECOMBINASE; CYCLIN D1; GLUTAMIC ACID; GLYCINE; K RAS PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ADENOCARCINOMA; ANIMALS; ANTHRACENES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE SILENCING; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; PANCREATIC NEOPLASMS;

EID: 84874453421     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12080     Document Type: Article

References (53)

1. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
2. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev 2002; 12: 14-21.
3. Chen YR, Meyer CF, Tan TH. Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gamma radiation-induced apoptosis. J Biol Chem 1996; 271: 631-4.
4. Guo YL, Baysal K, Kang B, Yang LJ, Williamson JR. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem 1998; 273: 4027-34.
5. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 36-42.
6. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med (Berl) 1996; 74: 589-607.
7. Miyazaki T, Bub JD, Iwamoto Y. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. Biochim Biophys Acta 2008; 1782: 593-604.
8. Sancho R, Nateri AS, de Vinuesa AG et al. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 2009; 28: 1843-54.
9. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 1999; 19: 1938-49.
10. Cui J, Han SY, Wang C et al. c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res 2006; 66: 10024-31.
11. Yang YM, Bost F, Charbono W et al. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003; 9: 391-401.
12. Shibata W, Maeda S, Hikiba Y et al. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res 2008; 68: 5031-9.
13. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006; 103: 10544-51.
14. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008; 118: 3943-53.
15. Chen F, Castranova V. Beyond apoptosis of JNK1 in liver cancer. Cell Cycle 2009; 8: 1145-7.
16. Chen N, Nomura M, She QB et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 2001; 61: 3908-12.
17. Tessari G, Ferrara C, Poletti A et al. The expression of proto-oncogene c-jun in human pancreatic cancer. Anticancer Res 1999; 19: 863-7.
18. Ennis BW, Fultz KE, Smith KA et al. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharmacol Exp Ther 2005; 313: 325-32.
19. Ijichi H, Chytil A, Gorska AE et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 2006; 20: 3147-60.
20. Ijichi H, Chytil A, Gorska AE et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 2011; 121: 4106-17.
21. Hingorani SR, Petricoin EF, Maitra A et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-50.
22. Chytil A, Magnuson MA, Wright CV, Moses HL. Conditional inactivation of the TGF-beta type II receptor using Cre:Lox. Genesis 2002; 32: 73-5.
23. Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet 2002; 32: 128-34.
24. Jackson EL, Willis N, Mercer K et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-8.
25. Bennett BL, Sasaki DT, Murray BW et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-6.
26. Sakamoto K, Maeda S, Hikiba Y et al. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009; 15: 2248-58.
27. Minden A, Lin A, McMahon M et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994; 266: 1719-23.
28. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995; 269: 1270-2.
29. Sherr CJ. D-type cyclins. Trends Biochem Sci 1995; 20: 187-90.
30. Müller H, Lukas J, Schneider A et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 1994; 91: 2945-9.
31. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50: 77-82.
32. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-58.
33. Luan J, Shattuck-Brandt R, Haghnegahdar H et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997; 62: 588-97.
34. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
35. Koga M, Kai H, Egami K et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 2008; 365: 279-84.
36. Castellà EM, Ariza A, Ojanguren I et al. Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study. Virchows Arch 1996; 429: 191-5.
37. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
38. Tong C, Yin Z, Song Z, et al., c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis. Am J Pathol 2007; 171: 297-303.
39. Bi X, Pohl NM, Yin Z, Yang W. Loss of JNK2 increases intestinal tumor susceptibility in Apc1638 + /- mice with dietary modulation. Carcinogenesis 2011; 32: 584-8.
40. Cellurale C, Sabio G, Kennedy NJ et al. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol 2011; 31: 1565-76.
41. Hayakawa Y, Hirata Y, Nakagawa H et al. Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer. Proc Natl Acad Sci USA 2011; 108: 780-5.
42. Gansauge S, Gansauge F, Ramadani M et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997; 57: 1634-7.
43. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998; 101: 344-52.
44. Albanese C, Johnson J, Watanabe G et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995; 270: 23589-97.
45. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-400.
46. Herber B, Truss M, Beato M, Müller R. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 1994; 9: 2105-7.
47. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 2000; 19: 2056-68.
48. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA, Holbrook NJ. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 2000; 20: 1713-22.
49. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
50. Itakura J, Ishiwata T, Friess H et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997; 3: 1309-16.
51. Ikeda N, Adachi M, Taki T et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999; 79: 1553-63.
52. Pagès G, Berra E, Milanini J, Levy AP, Pouysségur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000; 275: 26484-91.
53. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009; 125: 2323-31.